Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

"Cancer and systemic inflammation: treat the tumour and treat the host" article in the British Journal of Cancer (2014) 110, 1409–1412

"Abstract
Measurement of the systemic inflammatory response Relationship between systemic inflammatory response, symptom clusters and survival Treatment of cancer-associated symptoms in patients with anti-inflammatory agents Conclusion References Figures and Tables
Determinants of cancer progression and survival are multifactorial and host responses are increasingly appreciated to have a major role. Indeed, the development and maintenance of a systemic inflammatory response has been consistently observed to confer poorer outcome, in both early and advanced stage disease. For patients, cancer-associated symptoms are of particular importance resulting in a marked impact on day-to-day quality of life and are also associated with poorer outcome. These symptoms are now recognised to cluster with one another with anorexia, weight loss and physical function forming a recognised cluster whereas fatigue, pain and depression forming another. Importantly, it has become apparent that these symptom clusters are associated with presence of a systemic inflammatory response in the patient with cancer. Given the understanding of the above, there is now a need to intervene to moderate systemic inflammatory responses, where present. In this context the rationale for therapeutic intervention using nonselective anti-inflammatory agents is clear and compelling and likely to become a part of routine clinical practice in the near future. The published literature on therapeutic intervention using anti-inflammatory agents for cancer-associated symptoms was reviewed. There are important parallels with the development of useful treatments for the systemic inflammatory response in patients with rheumatological disease and cardiovascular disease."

Article at:
http://www.nature.com/bjc/journal/v110/n6/full/bjc201490a.html